GlassScriptPhysician profile
Cassie A Floyd Tyner
NPI 1881617728
$1,491.42
in general payments reported to CMS, 2019-2025
18 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $138 · 2021: $262 · 2022: $245 · 2023: $334 · 2024: $171 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $559.74 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $139.65 | 2025 | Fanapt |
| Lilly USA, LLC | $126.85 | 2020-2024 | Jardiance, Trulicity, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.54 | 2022-2025 | Caplyta |
| Pfizer INC. | $101.86 | 2020-2025 | |
| Uswm, LLC | $70.46 | 2023 | Zimhi, Lucemyra |
| Novo Nordisk INC | $68.26 | 2022-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $67.74 | 2020-2021 | |
| Indivior INC. | $45.76 | 2024-2025 | Sublocade |
| Merck Sharp & Dohme LLC | $41.12 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $37.77 | 2022 | |
| Glaxosmithkline, LLC. | $36.75 | 2022-2023 | Trelegy Ellipta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $29.38 | 2025 | |
| Amgen INC. | $14.07 | 2025 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $13.33 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $13.13 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.90 | 2021 | |
| Allergan, INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassie Floyd Tyner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.